You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies have agreed to combine their respective liquid handling platforms and analysis software for integrated sample-to-answer PCR workflows.
The partnership will help customers make evidence-based decisions regarding trial designs, companion diagnostics, and drug repurposing.
The firm will use the funds to accelerate clinical development and continued rollout of its RaDaR minimal residual disease (MRD) detection and recurrence assay.
The DNA mapping effort will collect 50,000 DNA samples from children as young as newborns, as well as any parents and siblings who wish to participate.
By bringing together epigenomic profiles for hundreds of tissue samples, researchers mapped regulatory modules relevant to a range of tissue and disease types.
The funding will be used to increase production of SARS-CoV-2 test kits in Meridian's Canadian facility and to build a new two-line production facility in Ohio.
The PCR-based test is designed for the epigenetic quantification of CD3+, CD4+, CD8+ T-, B-, and NK lymphocytes from a drop of fresh, frozen, or dried blood.
San Diego-based Decipher has a portfolio of genomic tests for urologic cancers to improve patient decision-making and accelerate adoption of new therapies.
University of Glasgow spinout Gabriel Precision Oncology will contribute a bioinformatics pipeline derived from cancer tissue samples to accelerate MDx adoption.
The firm's Discovery and Analytical Solutions business revenues grew 1 percent year over year, while its Diagnostics revenues more than doubled.
Most of the lineages, which were isolated between March 6 and Aug. 26, 2020, have unique mutations that haven't been identified elsewhere in the world.
A Geisinger and GeneDx team found exome sequencing can lead to a molecular diagnosis for 10 percent to 33 percent of people with cerebral palsy.
The company has started a program to increase access to tumor molecular profiling and precision oncology treatments for minority, low-income, and LGBTQ patients.
Waters' Q4 revenues were $786.7 million, up 10 percent from $716.3 million in Q4 2019, and above the consensus Wall Street estimate of $713.7 million.
The San Francisco-based precision oncology informatics company now has landed $166 million in equity investment since its inception in 2014.
The move will add Chronix's proprietary technology for blood-based immune therapy monitoring and transplant rejection testing to Oncocyte's existing test menu.
The firm said its Protein Sciences and Diagnostics and Genomics segments each saw record organic growth of 19 percent for the quarter.
The test, a version of the company's rapid SARS-CoV-2 assay, will be designed for both point-of-care and at-home use as an over-the-counter product.
The Swedish firm will use the proceeds from the private placement to finance its global marketing and sales expansion.
The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index last month, with Fulgent, Genetron, and Quidel leading the way.
The appellate court's decision deals a blow to a 2017 Columbia University lawsuit that alleged Illumina infringed one of the invalidated patents.
Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management.
Last week, GenomeWeb's readers were most interested in a study that described a new approach to find additional endogenous viruses hidden in the human genome.
Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares."
The company posted a Q4 net income of $2.50 billion, or $6.24 per share, up sharply from $1.00 billion, or $2.49 per share, during the same quarter last year.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.